Lifecore Biomedical makes sterile injectable drugs and medical devices under contract for pharmaceutical and biotechnology companies. LFCR reports earnings on Tue, Nov 3, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Craig-Hallum | Initiated | Buy | |
| Jun 16 | Barrington Research | Target raised | Buy | |
| Mar 17 | Barrington Research | Upgrade | Buy |
Seasonality
How LFCR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in LFCR in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LFCR is in one of them and how their past LFCR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LFCR in an article yet. Here's the latest on the wider market.
About Lifecore Biomedical, Inc. DE
Lifecore Biomedical is a contract development and manufacturing organization based in Chaska, Minnesota. It develops and makes sterile injectable drugs and medical devices, filled into syringes, vials and cartridges. The company also produces hyaluronic acid, made by fermentation, in bulk form and for use in injectables used in eye and joint treatments. Its customers include pharmaceutical, biotechnology and device companies that rely on its aseptic filling and regulatory expertise.
- Headquarters
- Chaska, MN